Adaptimmune

  • Home
  • Our Company
    • Overview arrow_forward
    • Board of Directors arrow_forward
    • Leadership Team arrow_forward
  • Products
  • Pipeline
    • Overview arrow_forward
    • Afami-cel arrow_forward
    • Lete-cel arrow_forward
    • Uza-cel arrow_forward
  • Technology
    • Overview arrow_forward
    • Manufacturing arrow_forward
    • Publications arrow_forward
  • Patients & Families
    • Overview arrow_forward
    • Taking Part in Our Clinical Trials arrow_forward
    • Videos arrow_forward
  • Clinical Trials
    • Overview arrow_forward
    • Expanded Access Policy arrow_forward
  • Investors & Media
    • Overview arrow_forward
    • News Center arrow_forward
    • Financial Info and Governance arrow_forward
    • Stock Data arrow_forward
    • SEC Filings arrow_forward
  • Contact
  • Careers
    • Overview arrow_forward
    • US Careers arrow_forward
    • UK Careers arrow_forward

Press Releases

Investors & Media

Investors & Media

  • Overview
  • News Center
    • Media Resources
    • Corporate Presentations
    • Press Releases
    • Publications
    • Events
    • Email Alerts
  • Financial Info and Governance
    • General Meeting (merger)
    • Company Information
    • Leadership Team
    • Financial Results
    • Income Statement
    • Balance Sheet
    • Cash Flow
    • Board of Directors
    • Board Committees
    • Governance Documents
    • Annual Shareholder Meeting
    • FAQ
    • Contacts
    • Adaptimmune Ltd Report
  • Stock Data
    • Quote
    • Charts
    • Historical Data
    • Analyst Coverage
  • SEC Filings
    • Overview
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • News Center

  • Media Resources
  • Corporate Presentations
  • Press Releases
  • Publications
  • Events
  • Email Alerts
Dec 01, 2015 7:00am EST

Adaptimmune and Universal Cells Announce Collaboration to Develop Allogeneic T-Cell Therapies

Nov 24, 2015 11:15am EST

Adaptimmune Initiates Phase I / II Trial Evaluating Its Affinity Enhanced T-Cell Therapy Targeting NY-ESO-1 in Patients With the Most Common Type of Lung Cancer

Nov 13, 2015 7:30am EST

Adaptimmune Reports First Quarter Financial Results for Fiscal Year 2015-16

Nov 12, 2015 10:17am EST

Adaptimmune to Participate in the Jefferies Autumn 2015 Global Healthcare Conference

Nov 05, 2015 8:15am EST

Adaptimmune Announces Data From Clinical Study of NY-ESO Affinity Enhanced T-Cell Therapy in Synovial Sarcoma at the 2015 Annual Meeting of the Society of Immunotherapy for Cancer (SITC)

Oct 30, 2015 9:00am EDT

Adaptimmune Announces Upcoming Data Presentation at the 2015 Annual Meeting of the Society of Immunotherapy for Cancer (SITC)

Oct 16, 2015 10:00am EDT

Adaptimmune to Participate in the 2015 BIO Investor Forum

Oct 13, 2015 6:00am EDT

Adaptimmune Reports Full Fiscal Year 2015 Financial Results

Oct 09, 2015 8:30am EDT

Adaptimmune Growth Leads to Long-Term Expansion Plans in Philadelphia

Oct 07, 2015 9:14am EDT

Adaptimmune to Report Full Fiscal Year 2015 Financial Results on October 13, 2015

RSS
  • Prev
  • 1...
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • Next
Adaptimmune
Disclosures Privacy Policy Disclaimer Search Sitemap Terms of Use Supply Terms Cookie Policy Manage Cookie Preferences
Linedin Twitter Youtube
© 2025 Adaptimmune. All Rights Reserved.